Current Report Filing (8-k)
July 10 2017 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 5, 2017
Achillion Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33095
|
|
52-2113479
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
300 George Street
New Haven, CT
|
|
06511
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(203) 624-7000
N/A
(Former name or former address, if changed since last report)
Check the appropriate box if the Form
8-K
is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c)).
|
Indicate by checkmark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
((§240.12b-2
of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers
On July 5, 2017, Joel C. Barrish, Ph.D., the Executive Vice President and
Chief Scientific Officer of Achillion Pharmaceuticals, Inc. (the Company), provided notice of his intention to resign from the Company. His resignation is effective July 14, 2017.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ACHILLION PHARMACEUTICALS, INC.
|
|
|
|
|
Date: July 10, 2017
|
|
|
|
By:
|
|
/s/ Mary Kay Fenton
|
|
|
|
|
|
|
Mary Kay Fenton
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024